Preliminary guidelines released by the National Institute for Health and Care Excellence do not recommend NHS funding for hyperkalaemia treatments Lokelma and Veltassa.
The Scottish Medicines Consortium has approved funding for four newly licensed medicines, expanding NHS treatments options in Scotland for ovarian cancer, lung cancer, urea cycle disorders and acute hereditary angioedema.